Market revenue in 2022 | USD 143.4 million |
Market revenue in 2030 | USD 275.1 million |
Growth rate | 8.5% (CAGR from 2022 to 2030) |
Largest segment | Lead identification & candidate optimization |
Fastest growing segment | Other Associated Workflow |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, Other Associated Workflow |
Key market players worldwide | Albany Molecular Research, Evotec SE, Labcorp Holdings Inc, GenScript ProBio, Pharmaceutical Product Development, Charles River Laboratories International Inc, Wuxi AppTec Co Ltd, Merck & Co Inc, Thermo Fisher Scientific Inc, Dalton Pharma Services, Jubilant Biosys, Qiagen NV, Eurofins Scientific SE, Dr. Reddy’s Laboratories, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, TCG Lifesciences, Syngene, Oncodesign, DiscoveRX, Domainex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug discovery outsourcing market will help companies and investors design strategic landscapes.
Lead identification & candidate optimization was the largest segment with a revenue share of 32.29% in 2022. Horizon Databook has segmented the Brazil drug discovery outsourcing market based on target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, other associated workflow covering the revenue growth of each sub-segment from 2018 to 2030.
The Brazilian market is expected to emerge as one of the promising drug discovery outsourcing markets owing to the increase in GDP of the country. Moreover, presence of untapped opportunities and ongoing studies in the region for the development of drug discovery are factors anticipated to drive the market growth.
For instance, Brazil joined Structural Genomics Consortium (SGC), an organization that supports discovery of new drugs through open access research and which helped establish the first open access research facility in Brazil.
The major goal of SGC is to perform science as well as technological development in all areas of biodiversity and drug discovery that rely on state-of-the-art methods of molecular & structural biology, synthetic organic chemistry, biology, natural products chemistry, biochemical & pharmacological assays, and medicinal chemistry & drug design.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil drug discovery outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil drug discovery outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account